What's new? Log in Free sign up

GlucoTrack (GCTK)

Company Profile

Company profile

Ticker

GCTK

Exchange

Website

www.glucotrack.com

CEO

Mr. Paul V. Goode Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Care and Social Assistance > Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Stryker • FS KKR Capital • Boston Scientific • Solventum • Becton, Dickinson and • Blackstone Secured Lending Fund • Boardwalk Pipeline Partners • Domtar • Golub Capital BDC ...

Former names

Integrity Applications, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

980668934

GCTK stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Prospectus supplement for primary offering

Entry into a Material Definitive Agreement

Definitive proxy

6 Dec 24

Glucotrack Announces Start of Enrollment for Human Clinical Study of Continuous Blood Glucose Monitor

Preliminary proxy

Entry into a Material Definitive Agreement

Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt

Quarterly report

Prospectus supplement with pricing info

Glucotrack, Inc. Announces Pricing of $10.0 Million Public Offering

Latest ownership filings

View all

JOHN BALLANTYNE

SABBY MANAGEMENT, LLC

James S Cardwell

Erin Catherine Carter

Financial summary

Financial statements Chart GCTK financial data

Quarter (USD)	Sep 24	Dec 23	Sep 23	Jun 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	356.00 k	356.00 k	356.00 k	356.00 k		356.00 k
Cash burn (monthly)	1.38 mm	54.75 k	1.08 mm	755.92 k		437.08 k
Cash used (since last report)	3.92 mm	155.45 k	3.08 mm	2.15 mm		1.24 mm
Cash remaining	-3.57 mm	200.55 k	-2.72 mm	-1.79 mm		-884.97 k
Runway (months of cash)	-2.6	3.7	-2.5	-2.4		-2.0

Beta Read what these cash burn values mean

Financial data from GlucoTrack earnings reports.

Institutional ownership, Q2 2024

GCTK institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	6	EXIT
Opened positions	0	5	EXIT
Closed positions	6	0	NEW
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0.00	261.68 mm	EXIT
Total shares	0.00	762.70 k	EXIT
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Sabby Management	0.00	-614.64 k	EXIT
Alerus Financial Na	0.00	-69.28 k	EXIT
Virtue Capital Management	0.00	-30.00 k	EXIT
Accurate Wealth Management	0.00	-22.10 k	EXIT
Susquehanna International	0.00	-13.68 k	EXIT
Renaissance Technologies	0.00	-13.00 k	EXIT
Proequities	0.00	0.00

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GCTK insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Jul 24	Paul Goode	Warrants to Purchase Common Stock Common Stock	Buy	Acquire P	No	No	4.95	42,000	207.90 k	42,000
1 Jul 24	Drew Sycoff	Warrants to Purchase Common Stock Common Stock	Buy	Acquire P	No	No	4.95	138,000	683.10 k	138,000
22 Apr 24	Drew Sycoff	Common Stock	Buy	Acquire P	No	No	1.26	182,539.6	230.00 k	2,951,257.6

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Glucotrack Announces Start Of Enrollment For Human Clinical Study Of Continuous Blood Glucose Monitor; Study Will Focus On The Co's Continuous Blood Glucose Monitor And Will Include Participants With Both Type 1 And Type 2 Diabetes

Feasibility study underway for the Company's novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8 weeksRutherford, NJ, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

S&P 500 Tops 6,000; Rumble Shares Slide After Q3 Results

Dow Jumps Over 150 Points; CyberArk Posts Upbeat Earnings

Press releases

From Benzinga Pro

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Detroit, Michigan--News Direct--By Joshua Enomoto, BenzingaIn the rapidly evolving medical technology sector, diabetes management specialist Glucotrack Inc. (NASDAQ:GCTK) aims to disrupt the present care framework for

Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt

Rutherford, NJ., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes,

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Detroit, Michigan--News Direct--By Josh Enomoto, BenzingaIntroduced in the late 1990s, continuous glucose monitoring (CGM) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring (BGM) methodologies –

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.